A routine blood panel comes back with one number slightly out of range, and suddenly you're staring at a word you've never seen before, wondering if you should be worried. That's how Daniel got here. He wrote to us after discovering he has Gilbert's syndrome, and what started as a personal lab result turned into a much bigger set of questions. Here's what he sent.
Daniel says: during routine blood work, he discovered mildly elevated unconjugated bilirubin caused by Gilbert's syndrome, a distinctive but generally harmless inherited condition. Reading about it opened the door to an entire world of genetic variation he hadn't really appreciated before — inborn errors of metabolism, or IEMs. Some are essentially benign, like Gilbert's. Others are compatible with a long, productive life if diagnosed and managed. Others are devastating or life-threatening from infancy. He wants to explore this landscape.
First question: when people talk about genetic diseases, are they usually referring to inborn errors of metabolism, or are IEMs just one relatively small subset within the much broader field of inherited disorders? How are genetic diseases typically classified, and where do IEMs fit into that picture?
Second, many IEMs are also classified as rare or orphan diseases, with such tiny patient populations that developing treatments can be scientifically and economically challenging. While healthcare policy deserves its own discussion, he wants to touch briefly on why so many metabolic disorders remain under-researched and how advances such as gene therapy, enzyme replacement, and newborn screening are changing the outlook.
Third, the methylation question. The term appears repeatedly in this field. What does methylation actually mean at the molecular level? Why is it so important in human biology? How many IEMs involve defects in methylation pathways, and how many affect completely different metabolic pathways? He also wants to understand why methylation has become such a popular concept online, and how to distinguish well-established metabolic disorders from claims that go beyond the current scientific evidence.
Finally, he wants a tour through the spectrum of inherited metabolic conditions — from relatively common and harmless examples like Gilbert's syndrome, through disorders like PKU, to some of the rarest and most severe IEMs — using them as a window into the extraordinary complexity of human metabolism and genetics.
That prompt takes us from one person's slightly unusual lab result to the entire architecture of human metabolism. Let's start by mapping the territory.
The first thing to know is that this field essentially begins with one man in 1902. Archibald Garrod was a British physician studying a condition called alkaptonuria — patients whose urine turns black when exposed to air. He noticed it ran in families, and he proposed something radical for the time: that a specific biochemical defect was inherited, and that defect caused the disease. He called it an inborn error of metabolism. It was the first time anyone had linked heredity to a concrete molecular step gone wrong.
Black urine is a memorable entry point.
It really is. And Garrod had this beautiful phrase — he talked about chemical individuality. The idea that each of us has a slightly different biochemical makeup, and sometimes those differences tip into disease. He was a century ahead of his time on that. Now, from that single condition in 1902, we've described approximately fourteen hundred and fifty distinct inborn errors of metabolism. And we're still finding new ones regularly as genomic sequencing picks up variants we didn't know to look for.
Fourteen hundred and fifty. So individually rare but collectively...
Collectively they're not rare at all. Depending on the population you're studying, estimates range from about one in eight hundred to one in twenty-five hundred live births affected by some form of IEM. That's a substantial number of people. Most of us have never heard of the vast majority of these conditions, but as a category they touch a lot of lives.
And that's the tension Daniel's getting at. His own condition is benign — a lab curiosity, really. But the same category contains disorders that kill infants within days if they're not caught.
And to answer his first question directly: no, when people talk about genetic diseases, they are not usually referring specifically to inborn errors of metabolism. IEMs are one subset within a much larger universe. The broad classification of genetic disease typically breaks into four big buckets. You've got single-gene disorders — also called Mendelian disorders — where a mutation in one gene causes the condition. IEMs live here, but so do things like cystic fibrosis, sickle cell disease, Huntington's disease. Then you've got chromosomal abnormalities — whole chromosomes missing, extra, or rearranged, like Down syndrome. Third, multifactorial conditions where multiple genes plus environment interact — things like heart disease, diabetes, many cancers. And fourth, mitochondrial disorders, which involve mutations in mitochondrial DNA and follow their own inheritance pattern.
So when Daniel's asking whether genetic disease mostly means IEMs, the answer is no — IEMs are a minority within even the single-gene bucket.
Right. And within that single-gene bucket, IEMs are further classified by the metabolic pathway they disrupt. Disorders of amino acid metabolism — PKU is the classic. Disorders of carbohydrate metabolism — galactosemia, where the body can't process galactose. Fatty acid oxidation disorders, organic acid metabolism disorders, lysosomal storage disorders like Gaucher and Fabry, and then disorders of bilirubin metabolism, which is where Gilbert's syndrome sits. Each category represents a different stretch of the vast chemical factory that keeps us alive.
Let's sit with Gilbert's for a minute, because it's the anchor of Daniel's question and it's a perfect illustration of how these things work at the molecular level.
Gilbert's syndrome is genuinely elegant in its simplicity. You have a gene called UGT1A1. It codes for an enzyme called UDP-glucuronosyltransferase — I'm going to say glucuronosyltransferase once and then never again.
Appreciated.
This enzyme's job is to take bilirubin, which is a breakdown product of hemoglobin, and attach a sugar molecule to it. That process is called conjugation, and it makes the bilirubin water-soluble so your body can excrete it. In Gilbert's syndrome, there's a polymorphism — a variation — in the promoter region of the UGT1A1 gene. The promoter is the on-off switch. This particular variation means the switch doesn't work at full power. Enzyme activity drops to about thirty percent of normal.
Thirty percent sounds alarming.
It sounds alarming, but here's the thing — thirty percent is plenty for normal life. What happens is that unconjugated bilirubin builds up slightly in the blood. It's usually caught on a routine panel where everything else is normal except that one number is mildly elevated. And it can become more noticeable during fasting, illness, stress, or dehydration. But it causes no liver damage, no long-term harm, no reduced lifespan. Three to ten percent of the population has it. Most never know.
So Daniel's lab result is essentially his liver's enzyme working at partial capacity, and that partial capacity is completely adequate unless you stress the system.
And it's worth knowing about because it prevents unnecessary workups. A doctor who isn't familiar with Gilbert's might see elevated bilirubin and start investigating liver disease or biliary obstruction. Knowing you have it saves you from that cascade.
The benign end of the spectrum, then. Now let's get into the part of Daniel's question that I think trips a lot of people up — the methylation piece. He says the term appears repeatedly, and he wants to know what it actually means and why it's everywhere online.
This is where we need to make a distinction that most popular discussions completely miss. At the molecular level, methylation is simply the addition of a methyl group — one carbon atom and three hydrogens, CH3 — to another molecule. That's it. It's a tiny chemical tag. But what that tag does depends entirely on what it's attached to. And there are two completely different contexts that get hopelessly conflated.
Lay them out.
The first is epigenetic DNA methylation. This is where methyl groups are attached directly to DNA, usually at positions called CpG sites. This doesn't change the genetic code — it changes whether a gene is turned on or off. It's gene regulation. This is the methylation people talk about when they discuss how environment shapes gene expression, how trauma might be inherited, how aging affects the genome. It's fascinating biology, and it's mostly not what we're talking about with inborn errors of metabolism.
And the second?
The second is metabolic methylation. This is where methyl groups are transferred between small molecules as part of normal biochemistry. The body uses a compound called S-adenosylmethionine, or SAM, as its universal methyl donor. SAM hands off methyl groups to dozens of different targets — it's used to make creatine, to break down histamine, to synthesize neurotransmitters, to process homocysteine. This is intermediary metabolism, and it's where the actual IEMs involving methylation live.
So when we talk about methylation disorders as inborn errors of metabolism, we're talking about the second kind.
Almost entirely. And here's the key point: the vast majority of IEMs do not involve methylation pathways at all. Amino acid disorders, carbohydrate disorders, fatty acid oxidation disorders, lysosomal storage disorders — none of these are methylation problems. The methylation-related IEMs are a small, specific subset.
Give me examples of the real ones.
Homocystinuria is the classic. It's caused by a deficiency in cystathionine beta-synthase, an enzyme that processes homocysteine using — you guessed it — a methyl group transfer. Homocysteine builds up to toxic levels. It causes intellectual disability, lens dislocation, skeletal abnormalities, and a massively increased risk of blood clots. But here's what's remarkable: many patients respond to high-dose vitamin B6, which is a cofactor for the enzyme, and betaine, which provides an alternative methylation pathway to clear the homocysteine. It's a methylation disorder with a treatment that directly leverages methylation biochemistry.
That's elegant. What else?
True MTHFR deficiency. Not the common polymorphism — I'll get to that — but actual MTHFR deficiency, where the enzyme methylenetetrahydrofolate reductase is severely impaired. This is rare and devastating. It causes severe neurological problems, microcephaly, apnea, and can be fatal in infancy. Then there are disorders of creatine synthesis, like GAMT deficiency — guanidinoacetate methyltransferase deficiency — where the body can't make creatine, which is essential for energy metabolism in muscle and brain.
Three rare, severe conditions. Now contrast that with what people actually encounter when they google methylation.
This is where the wellness industry has built an empire on a misunderstanding. The MTHFR gene has a common variant called C677T. About ten to fifteen percent of the population is homozygous for it — meaning they have two copies. It reduces enzyme activity somewhat, but it is not a disease. It does not cause the symptoms attributed to it in countless blog posts and supplement marketing materials. You will find claims that MTHFR variants cause everything from fatigue to autism to depression to infertility, and that you need specialized methylation support supplements to fix it.
And the supplement market is...
Lucrative. Methylated B vitamins, special folate formulations, detox protocols. None of it is supported by evidence for people with common polymorphisms. The gap between a true MTHFR deficiency — which is a severe IEM caught on newborn screening or presenting in infancy — and having a C677T variant is the gap between a disease and a normal human variation.
That's the distinction Daniel's asking us to help him make. Established metabolic disorder versus claim beyond the evidence.
The three criteria are: does it have a clear biochemical phenotype you can measure in a lab? Does it have reproducible diagnostic criteria that aren't just symptom checklists? And are there evidence-based treatments that improve outcomes in controlled studies? Real IEMs check all three boxes. Wellness methylation claims typically check none.
So we've seen the molecular machinery. But knowing what these diseases are raises a harder question: what do we do about them, especially when each one affects only a handful of people?
This is the rare disease economics problem, and it's difficult. Most IEMs affect fewer than one in two thousand people, which is the threshold for what's called an orphan disease. When your potential patient population is measured in hundreds or thousands, the traditional pharmaceutical business model breaks. You can't recoup development costs through volume.
And yet we have treatments.
We do, and the turning point was the Orphan Drug Act of 1983. Before that, there were something like thirty-four approved orphan drugs total. The act created three incentives: tax credits for clinical research, a period of market exclusivity — seven years where no competitor could sell the same drug for the same indication — and direct grant funding for development. It worked. We're now at nearly eight hundred approved orphan therapies.
Seven years of exclusivity for a drug that might have no competitors anyway because the market is so small — that's clever incentive design.
It is, but it's also created some perverse outcomes. Companies have learned to slice diseases into ever-narrower indications to qualify for orphan status, or to take existing drugs and repurpose them for rare diseases at astronomical prices. The same incentives that brought us enzyme replacement therapy for Gaucher disease also brought us a drug that costs three hundred thousand dollars a year per patient.
Let's talk about the genuine successes though. Newborn screening — Daniel mentioned it.
Newborn screening is the quiet revolution in this field. It started with PKU in the 1960s. Robert Guthrie developed a simple bacterial inhibition assay on a dried blood spot from a heel prick. If the baby had PKU, the blood spot would show elevated phenylalanine. It was cheap, it was scalable, and it meant you could catch the disease before irreversible brain damage occurred.
And now?
Now we use tandem mass spectrometry. A single dried blood spot from a newborn's heel can be screened for thirty to fifty conditions simultaneously. The machine measures the mass of molecules in the sample and can detect abnormal patterns of amino acids and acylcarnitines that signal specific metabolic disorders. It's one of the most cost-effective public health interventions ever devised.
PKU itself — walk me through it as the paradigm case.
Phenylketonuria. Deficiency of phenylalanine hydroxylase, the enzyme that converts the amino acid phenylalanine into tyrosine. Without it, phenylalanine builds up in the blood and becomes toxic to the developing brain. Prevalence is about one in ten thousand to fifteen thousand live births. Before newborn screening, these children developed severe intellectual disability, seizures, and behavioral problems. Now, if you catch it at birth and put the child on a low-phenylalanine diet — special medical formulas, carefully measured protein intake — they develop normally.
A dietary disease managed by diet. That's satisfying.
It gets better. There's now a drug called sapropterin — brand name Kuvan — that's a synthetic form of the BH4 cofactor. For some patients with residual enzyme activity, it boosts what little function remains. And there's a newer enzyme substitution therapy called pegvaliase that can actually break down phenylalanine in the bloodstream. We've gone from diet alone to a multi-pronged treatment strategy for a disease that was a death sentence for the intellect sixty years ago.
And for the lysosomal storage disorders — Gaucher, Fabry, Pompe — the approach is different.
Enzyme replacement therapy. These are conditions where the lysosome — the cell's recycling center — is missing an enzyme that breaks down specific molecules. Those molecules accumulate, and cells eventually die. Gaucher disease was the first success story. In 1991, imiglucerase was approved — a recombinant form of the missing enzyme, glucocerebrosidase, delivered by intravenous infusion every two weeks. Before this, the severe forms of Gaucher caused bone crises, massive organ enlargement, and early death. Now patients manage it as a chronic condition.
Infusion every two weeks for life.
For life. And it's expensive — these are biologic drugs manufactured in sophisticated cell culture systems. But they work. Pompe disease, Fabry disease, several mucopolysaccharidoses — all now have enzyme replacement options. The next frontier is gene therapy.
Where are we with that?
The promise is enormous and the challenges are real. The idea is to deliver a working copy of the defective gene to the patient's cells, so their own body produces the missing enzyme permanently. We've seen approvals in related fields — hemophilia gene therapy is now a reality, spinal muscular atrophy gene therapy has transformed outcomes for infants who would otherwise die before age two. For IEMs, the hurdles are delivery and immune response. You need to get the gene to the right tissues — liver for many metabolic disorders, brain for others — and you need the immune system not to attack the viral vector or the newly expressed protein.
And the economics of a one-time treatment for a tiny patient population...
Are brutal. A gene therapy can cost one to three million dollars per patient. Health systems struggle with that math even when the alternative is a lifetime of enzyme replacement that costs more over time. The payment models are still being invented — installment plans, outcomes-based pricing, annuity models. It's a fascinating intersection of science, economics, and ethics.
Let's bring this back to what it means for Daniel and for anyone listening who might have gotten a genetic result they don't know what to do with. You've got Gilbert's syndrome. What do you actually do with that information?
You do almost nothing. And that's the good news. Gilbert's syndrome requires no treatment, no dietary restrictions, no monitoring beyond knowing you have it. The main practical value is that it explains lab results that would otherwise trigger concern. If you're fasting, stressed, or fighting an infection, your bilirubin might tick up a bit more than usual. That's expected. It also affects the metabolism of a few drugs — irinotecan, a chemotherapy agent, is the most clinically significant — but for the vast majority of medications, it's irrelevant.
So the intervention is knowledge.
Tell your doctor, have it in your chart, and otherwise forget about it. Compare that to PKU, where dietary management starts in the first week of life and continues indefinitely. Or to maple syrup urine disease, where a missed diagnosis means catastrophic neurological damage within days. Same category — inborn errors of metabolism — but the spectrum of severity is almost incomprehensibly wide.
That spectrum is what I keep coming back to. Gilbert's at three to ten percent of the population, benign. PKU at one in ten thousand, manageable with early intervention. Then conditions like classic galactosemia, where a newborn given milk goes into rapid decline because they can't process galactose — liver failure, sepsis, death if you don't catch it immediately.
Or medium-chain acyl-CoA dehydrogenase deficiency — MCADD. A fatty acid oxidation disorder. These children are perfectly healthy until they have a period of fasting — a stomach bug, maybe, where they're not eating. Then their body tries to switch to fat for energy and can't complete the process. They develop hypoglycemia, vomiting, lethargy, and can die or suffer brain damage. But if you know they have it, you simply make sure they never go more than a few hours without eating, especially when sick. Simple intervention, catastrophic without it.
That's what makes the newborn screening panel so remarkable. A heel prick, a mass spectrometer, and you catch conditions that are invisible until they're emergencies.
And the panel keeps expanding. Different states and countries screen for different numbers of conditions, but the recommended uniform screening panel in the United States now covers something like thirty-five core conditions and twenty-six secondary conditions. Every one of those has an intervention that changes the outcome. That's the criterion for inclusion — you don't screen for something you can't treat.
Daniel's final question was about the bigger picture — using these conditions as a window into human metabolism. What's the view?
The view is that human metabolism is not a single blueprint. It's a distribution. Every enzyme in your body is encoded by a gene, and every gene has variants in the population. Most variants are silent or subtle. Some, like the UGT1A1 polymorphism in Gilbert's, produce a measurable but harmless difference. A smaller number produce disease when you inherit two copies. And a very small number are lethal.
So we all walk around with dozens of minor metabolic quirks.
Hundreds, probably. Most we'll never know about because they never cause a problem. They're just part of the chemical individuality Garrod talked about in 1902. What's shifted is our ability to detect them. Direct-to-consumer genetic testing can now tell you about your MTHFR status, your carrier status for various recessive conditions, your pharmacogenetic variants. The technology has raced ahead of our ability to interpret what it means.
That's where the wellness industry rushes in.
Into the gap between data and meaning. A common polymorphism is not a disease. A carrier status is not a diagnosis. A variant of uncertain significance is exactly what it sounds like — uncertain. But uncertainty doesn't sell supplements. Certainty does, even when it's fake.
So for someone like Daniel, who's gone down this rabbit hole and is trying to sort signal from noise — what's the framework?
First, if you have a specific diagnosis — Gilbert's, PKU, whatever it is — understand what it actually means at the biochemical level. Not what a forum says it means. What does the enzyme do? What builds up? What's the consequence? Second, if you're looking at genetic testing results, distinguish between polymorphisms and pathogenic mutations. A polymorphism is common. It's a normal variant. A pathogenic mutation is rare and causes disease. Third, if someone is trying to sell you supplements based on your genetic variants, ask what the randomized controlled trial evidence is. There usually isn't any.
And for Gilbert's specifically — Daniel, you're fine. Your liver is just a little lazy at conjugating bilirubin, and thirty percent capacity is more than enough.
More than enough. And you now have the distinction of carrying one of the most common inborn errors of metabolism in the human species. Wear it as a conversation starter.
Which brings us to the open question. As newborn screening expands and gene therapy advances, our ability to detect and intervene in metabolic differences is going to keep growing. We're going to find more and more conditions that sit in the gray zone — not benign like Gilbert's, not devastating like classic galactosemia, but somewhere in between. Where do we draw the line between variation and disease?
That's the question that's going to define this field for the next generation. Every expansion of the newborn screening panel involves a debate about exactly this. You're identifying children who might never develop symptoms, or whose symptoms might be mild, and you're labeling them with a disease. There's a whole category called biochemical phenotypes — you have the lab abnormality, but whether it causes clinical problems is uncertain. We're going to need a much more nuanced language for this.
The boundary between disease and variation is blurring, and we're the ones holding the eraser.
We are. And honestly, I think that's a good problem to have. It means we're seeing human biology at a resolution Garrod could only dream of. The challenge is keeping our interpretation as sophisticated as our technology.
We want to hear from listeners who've discovered their own metabolic quirks — whether it's Gilbert's, a carrier status, or something you're still trying to understand. Send us your stories and questions.
Thanks as always to our producer Hilbert Flumingtop, who keeps this operation running.
This has been My Weird Prompts. Find every episode at my weird prompts dot com, and if you've got a prompt for us, email the show at show at my weird prompts dot com.
We'll be back soon.
